Compare Aurobindo Pharma with Natco Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AUROBINDO PHARMA vs NATCO PHARMA - Comparison Results

AUROBINDO PHARMA     Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AUROBINDO PHARMA NATCO PHARMA AUROBINDO PHARMA/
NATCO PHARMA
 
P/E (TTM) x 18.5 33.8 54.6% View Chart
P/BV x 4.0 4.8 83.1% View Chart
Dividend Yield % 0.3 0.7 37.5%  

Financials

 AUROBINDO PHARMA   NATCO PHARMA
EQUITY SHARE DATA
    AUROBINDO PHARMA
Mar-19
NATCO PHARMA
Mar-19
AUROBINDO PHARMA/
NATCO PHARMA
5-Yr Chart
Click to enlarge
High Rs830849 97.8%   
Low Rs527557 94.6%   
Sales per share (Unadj.) Rs333.9573.8 58.2%  
Earnings per share (Unadj.) Rs40.4176.0 22.9%  
Cash flow per share (Unadj.) Rs51.8198.2 26.1%  
Dividends per share (Unadj.) Rs2.506.25 40.0%  
Dividend yield (eoy) %0.40.9 41.4%  
Book value per share (Unadj.) Rs237.1842.7 28.1%  
Shares outstanding (eoy) m585.9136.50 1,605.2%   
Bonus/Rights/Conversions ESOPBB-  
Price / Sales ratio x2.01.2 165.9%   
Avg P/E ratio x16.84.0 421.0%  
P/CF ratio (eoy) x13.13.5 369.6%  
Price / Book Value ratio x2.90.8 343.1%  
Dividend payout %6.23.6 174.4%   
Avg Mkt Cap Rs m397,56925,660 1,549.4%   
No. of employees `00017.95.0 360.2%   
Total wages/salary Rs m25,8493,559 726.3%   
Avg. sales/employee Rs Th10,956.94,225.3 259.3%   
Avg. wages/employee Rs Th1,447.7718.0 201.6%   
Avg. net profit/employee Rs Th1,324.31,295.9 102.2%   
INCOME DATA
Net Sales Rs m195,63620,945 934.0%  
Other income Rs m1,5531,302 119.3%   
Total revenues Rs m197,18922,247 886.4%   
Gross profit Rs m39,5197,948 497.2%  
Depreciation Rs m6,680810 824.6%   
Interest Rs m2,626193 1,360.6%   
Profit before tax Rs m31,7678,247 385.2%   
Minority Interest Rs m270-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-8810-   
Tax Rs m7,2691,823 398.7%   
Profit after tax Rs m23,6456,424 368.1%  
Gross profit margin %20.237.9 53.2%  
Effective tax rate %22.922.1 103.5%   
Net profit margin %12.130.7 39.4%  
BALANCE SHEET DATA
Current assets Rs m153,64523,472 654.6%   
Current liabilities Rs m120,4297,287 1,652.7%   
Net working cap to sales %17.077.3 22.0%  
Current ratio x1.33.2 39.6%  
Inventory Days Days13592 146.6%  
Debtors Days Days6488 72.2%  
Net fixed assets Rs m103,90918,648 557.2%   
Share capital Rs m586365 160.5%   
"Free" reserves Rs m138,32234,525 400.6%   
Net worth Rs m138,90830,760 451.6%   
Long term debt Rs m1,8000-   
Total assets Rs m264,54443,031 614.8%  
Interest coverage x13.143.7 29.9%   
Debt to equity ratio x00-  
Sales to assets ratio x0.70.5 151.9%   
Return on assets %9.915.4 64.6%  
Return on equity %17.020.9 81.5%  
Return on capital %23.827.4 86.9%  
Exports to sales %49.60-   
Imports to sales %18.80-   
Exports (fob) Rs m97,091NA-   
Imports (cif) Rs m36,741NA-   
Fx inflow Rs m97,31611,536 843.6%   
Fx outflow Rs m40,5892,939 1,381.1%   
Net fx Rs m56,7278,597 659.8%   
CASH FLOW
From Operations Rs m16,2206,688 242.5%  
From Investments Rs m-28,768-6,122 469.9%  
From Financial Activity Rs m19,191-509 -3,770.3%  
Net Cashflow Rs m6,65666 10,085.5%  

Share Holding

Indian Promoters % 54.1 52.0 104.0%  
Foreign collaborators % 0.0 1.5 -  
Indian inst/Mut Fund % 8.0 7.8 101.4%  
FIIs % 27.7 16.6 166.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.2 26.0 39.2%  
Shareholders   69,601 25,395 274.1%  
Pledged promoter(s) holding % 8.6 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AUROBINDO PHARMA With:   PIRAMAL ENTERPRISES  GSK PHARMA  FRESENIUS KABI ONCO.  DR. REDDYS LAB  ABBOTT INDIA  

Compare AUROBINDO PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

5 Reasons Why Sensex Plunged 536 Points Today(Closing)

Extending losses to the fifth straight session, Indian share markets witnessed selling pressure throughout the day today and ended deep in the red.

Related Views on News

AUROBINDO PHARMA Announces Quarterly Results (1QFY21); Net Profit Up 25.6% (Quarterly Result Update)

Sep 15, 2020 | Updated on Sep 15, 2020

For the quarter ended June 2020, AUROBINDO PHARMA has posted a net profit of Rs 8 bn (up 25.6% YoY). Sales on the other hand came in at Rs 59 bn (up 8.8% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (4QFY20); Net Profit Up 48.2% (Quarterly Result Update)

Jun 5, 2020 | Updated on Jun 5, 2020

For the quarter ended March 2020, AUROBINDO PHARMA has posted a net profit of Rs 9 bn (up 48.2% YoY). Sales on the other hand came in at Rs 62 bn (up 16.4% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

NATCO PHARMA Announces Quarterly Results (3QFY20); Net Profit Down 34.5% (Quarterly Result Update)

Feb 17, 2020 | Updated on Feb 17, 2020

For the quarter ended December 2019, NATCO PHARMA has posted a net profit of Rs 1 bn (down 34.5% YoY). Sales on the other hand came in at Rs 5 bn (down 13.4% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (3QFY20); Net Profit Down 0.5% (Quarterly Result Update)

Feb 7, 2020 | Updated on Feb 7, 2020

For the quarter ended December 2019, AUROBINDO PHARMA has posted a net profit of Rs 7 bn (down 0.5% YoY). Sales on the other hand came in at Rs 58 bn (up 10.1% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (2QFY20); Net Profit Up 4.6% (Quarterly Result Update)

Nov 15, 2019 | Updated on Nov 15, 2019

For the quarter ended September 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 4.6% YoY). Sales on the other hand came in at Rs 56 bn (up 17.9% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

More Views on News

Most Popular

Time to Book Profits in Pharma Stocks(Fast Profits Daily)

Jan 15, 2021

In this video, I'll show you why it might be the right time to take money of the table in pharma stocks.

Smallcap Stocks: Your Best Bet for 2021 and Beyond(Profit Hunter)

Jan 15, 2021

The pandemic failed to thwart Richa's investing success formula for 2020.

One Chart to See Before You Sell(Fast Profits Daily)

Jan 22, 2021

In this video, I'll show you a crucial chart that you need to check before you decide to sell any stock or index.

Invest in the Multibaggers of 2021 and Beyond(Profit Hunter)

Jan 21, 2021

Our ace stock picker is ready to capitalise on a big growth opportunity.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

AUROBINDO PHARMA SHARE PRICE


Jan 28, 2021 03:36 PM

TRACK AUROBINDO PHARMA

  • Track your investment in AUROBINDO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON AUROBINDO PHARMA

AUROBINDO PHARMA 8-QTR ANALYSIS

COMPARE AUROBINDO PHARMA WITH

MARKET STATS